Full-Time

Software Engineer 1

Danaher Corporation

Danaher Corporation

10,001+ employees

Water quality, diagnostics, product identification solutions

Compensation Overview

$68k - $75k/yr

+ Bonus/Incentive Pay

No H1B Sponsorship

Indianapolis, IN, USA

In Person

On-site role in Indianapolis, Indiana.

Category
Software Engineering (1)
Required Skills
gRPC
Java
.NET
C#
REST APIs

People at Danaher Corporation

People at Danaher Corporation who can refer or advise you

Requirements
  • Bachelor’s degree in computer science, software engineering, or related field
  • 0-2+ years of professional software development experience
  • Strong verbal and written English communication skills
  • Some experience in C#/.NET (Java experience also considered)
  • Work Authorization Requirement: Applicants must be legally authorized to work in the United States at the time of application; not eligible for current or future employment visa sponsorship; candidates should indicate if they require current or future sponsorship
Responsibilities
  • Develop and maintain device integrations for custom liquid handling robotic systems across multiple communication protocols (REST, gRPC, Serial, Web Sockets, SiLA)
  • Work cross functionally with hardware, systems and application scientists to develop new product offerings
  • Partner with scientists and lab automation engineers to diagnose and resolve integration issues across APIs, services, and third-party devices
  • Debug system behavior across hardware/software boundaries, including timing, communication, and scheduling interactions
Desired Qualifications
  • WPF or desktop application development
  • Containerization and Orchestration technology (e.g. Docker, Podman, Kubernetes)
  • Troubleshooting network-related issues (latency, connectivity, DNS resolution)
  • Hardware integrations or lab automation systems

Danaher focuses on three main areas: water quality, product identification, and diagnostics, serving municipal, industrial, and healthcare customers. In water quality, it supplies precision instruments and purification technologies to analyze, treat, and manage water across various settings. In product identification, it leads in laser marking, coding, engraving, packaging solutions, and color science to ensure accurate labeling and product traceability. In diagnostics, it provides automated tools and software for medical testing and point-of-care care, all guided by the Danaher Business System that drives continuous improvement; the company aims to improve water safety, supply-chain traceability, and healthcare outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Washington DC, District of Columbia

Founded

1969

People at Danaher Corporation

People at Danaher Corporation who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Masimo acquisition adds $0.15–$0.20 to adjusted EPS in first year, scaling to $0.70 by year five.
  • Equipment orders grew 30% year-over-year in Q1 2026 due to reshoring and pharmaceutical pipeline investment.
  • $2.7B Swiss franc notes issuance with maturities to 2056 strengthens long-term capital flexibility.

What critics are saying

  • Apple patent dispute could trigger injunctions eroding $9.9B deal accretion within 12–18 months.
  • $9.9B acquisition plus CHF notes raise leverage to ~4.5x, constraining water-quality and product-identification R&D capex.
  • Masimo’s standalone structure may delay AI integration, risking loss of FDA momentum to GE Healthcare in 9–15 months.

What makes Danaher Corporation unique

  • Danaher focuses exclusively on life sciences and diagnostics after spinning off Veralto in 2024.
  • It operates the Danaher Business System driving continuous improvement and superior financial performance.
  • The company leads in diagnostics with AI-enabled opioid monitoring tech cleared by FDA in July 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Limited

Paid Vacation

Paid Holidays

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Fertility Treatment Support

Family Planning Benefits

Adoption Assistance

Childcare Support

Elder Care Support

Parental Leave

Parental Leave

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Employee Discounts

Meal Benefits

Relocation Assistance

Pet Insurance

Commuter Benefits

Bereavement Leave

Training Programs

Educational Allowance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Healthcare Savings Account

Flexible Spending Account

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-8%

2 year growth

-9%
Ololand AI
Jun 26th, 2026
Merck cements Life Science leadership with $11.3B Bio-Techne acquisition.

Merck cements Life Science leadership with $11.3B Bio-Techne acquisition. Friday, June 26, 2026 The life science tools market is heating up with Merck's blockbuster $11.3 billion acquisition of Bio-Techne. This strategic move is designed to cement the company's leadership in a rapidly growing sector and signals a major consolidation trend that is actively reshaping the industry for competitors and investors alike. Audio Brief (2:45 listen) The life science tools market, the critical "picks and shovels" infrastructure for the biopharmaceutical revolution, is witnessing a significant consolidation wave. In a landscape where scale and portfolio breadth are paramount, major players are aggressively pursuing M&A to secure long-term growth and competitive advantage. The latest blockbuster move comes from Merck, which has announced a definitive agreement to acquire Bio-Techne for an enterprise value of approximately $11.3 billion. This transaction is more than a simple expansion; it's a calculated maneuver to fortify Merck's leadership in high-growth areas like cell and gene therapy, proteomics, and diagnostics, signaling an intensified competitive environment for peers like Thermo Fisher Scientific and Danaher. A strategic bolt-on to cement leadership. Merck's acquisition of Bio-Techne is a clear reflection of its strategy to build an end-to-end offering for the biopharma industry through its Life Science business sector. While Merck already possesses a formidable portfolio, particularly in bioprocessing (the manufacturing of biologic drugs), the addition of Bio-Techne provides critical assets in the upstream research and discovery and quality control phases. * Strategic Rationale: The primary driver for this deal is the complementary nature of the two portfolios. Bio-Techne is a market leader in high-quality proteins, antibodies, and immunoassays - essential, high-margin consumables used extensively in academic research, drug discovery, and clinical diagnostics. These products fit seamlessly into Merck's existing research solutions business, creating significant cross-selling opportunities. By integrating Bio-Techne's reagent and small instrument capabilities, Merck can offer its customers a more comprehensive workflow solution, from initial discovery to final manufacturing. * Valuation Context: The US$73 per share cash offer, representing an $11.3 billion enterprise value, reflects the high strategic value placed on premium life science assets. Companies like Bio-Techne are highly attractive due to their strong brand recognition, intellectual property, and "razor-and-blade" business model, which generates predictable, recurring revenue from consumables. While the implied valuation multiple is substantial, it is in line with recent transactions in the sector, where acquirers are willing to pay a premium for assets that offer both market leadership and exposure to the fastest-growing segments of healthcare innovation. * Market Positioning: This deal significantly strengthens Merck's position as one of the top-tier suppliers to the global life science industry. It narrows the gap with larger, more diversified competitors and enhances Merck's "one-stop-shop" appeal. For large pharmaceutical and emerging biotech clients, the ability to source a wider range of critical reagents and instruments from a single, trusted partner simplifies procurement and can de-risk their supply chains - a crucial consideration in the post-pandemic era. Reshaping the competitive landscape. Merck's move is set to send ripples across the life science tools sector, forcing competitors to reassess their own strategic positions. The industry has long been characterized by a race for scale, and this acquisition raises the stakes considerably. For decades, the market has been dominated by a handful of large consolidators. This transaction reaffirms that aggressive M&A remains the primary tool for growth and market share capture. Competitors will now face a more formidable Merck, armed with a deeper portfolio in proteomics and diagnostics. This will likely spur further consolidation as other players look to fill gaps in their own offerings or acquire new technologies to stay competitive. The acquisition particularly amplifies Merck's capabilities in the burgeoning cell and gene therapy (CGT) space. Bio-Techne provides critical analytical and quality control tools used to characterize and release these complex therapies. By combining these with its own viral vector manufacturing solutions, Merck can offer a more integrated and compelling value proposition to CGT developers, a market segment poised for exponential growth. This strategic depth will be difficult for smaller, more specialized players to replicate. The path forward. The successful integration of Bio-Techne will be the immediate focus for Merck's leadership. Capturing the promised revenue and cost synergies will require a deft hand in merging distinct corporate cultures and aligning complex product roadmaps and sales channels. However, the strategic logic underpinning the deal appears sound and compelling. This acquisition is a bold statement of intent from Merck. It underscores a commitment to leading the life science tools market not just in established areas like bioprocessing but across the entire research and development continuum. For the industry at large, it signals that the era of transformative M&A is far from over. As the pace of biomedical innovation continues to accelerate, the race to supply the scientists and manufacturers on the front lines will only grow more intense. Analyze your own CIM. Upload a CIM and get financials, risks, and valuation in seconds.

The Scientist
Jun 23rd, 2026
Versant Diagnostics expands collaboration with Leica Biosystems as PRW Laboratories becomes first to deploy Aperio GT Elite solution.

Versant Diagnostics expands collaboration with Leica Biosystems as PRW Laboratories becomes first to deploy Aperio GT Elite solution. Milestone deployment reflects growing demand for high-throughput, AI-enabled digital pathology workflows Leica Biosystems Listen with Speechify Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Versant Diagnostics, an independent physician services company actively engaged in next-generation digital pathology, announce an expanded collaboration to advance digital pathology adoption. PRW Laboratories, in partnership with Versant Diagnostics and Versant DermPath, has become the world's first laboratory to deploy the recently launched Aperio GT Elite solution. Designed for high-throughput, time-critical digital pathology workflows, the Aperio GT Elite scanner helps accelerate slide processing and review with minimal manual intervention and rework. It can scan as fast as 22 seconds per slide and integrate LIS data to drive automated scanning protocols based on criteria such as tissue or stain type. "For digital pathology to truly advance, innovation must translate into faster, more confident decisions for laboratories and ultimately, the patients they serve," said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. "With the Aperio GT Elite, we are leveraging our deep pathology expertise to help customers move from slide to insight faster through a connected, high-throughput workflow that reduces manual steps and adapts to their real-world needs. This launch reflects our long-term commitment to delivering scalable, end-to-end solutions that enable labs to adopt digital pathology with confidence and accelerate the impact of every review." The deployment reflects growing adoption of high-throughput, AI-enabled digital pathology workflows and builds on a longstanding collaboration between Leica Biosystems and Versant Diagnostics. Before adding the Aperio GT Elite solution, Versant Diagnostics leveraged the Leica Biosystems Aperio GT 450 scanner to digitize whole-slide images, alongside Indica Labs' HALO AP(R) document as their image management solution. "When we started our digital journey, we weren't simply looking for an equipment vendor - we were looking for a true partner who shared our vision for the future of patient care," said Lola Leibensperger, Versant Diagnostics' Chief Operating Officer. "Becoming the first laboratory network in the world to implement Leica Biosystems' Aperio GT Elite scanners at Versant Diagnostics and PRW Laboratories is a testament to that shared commitment. This milestone isn't just about adopting cutting-edge technology; it's about pioneering digital innovation together to enhance accuracy, streamline laboratory workflows, and ultimately deliver faster, more precise diagnostics for the patients who depend on us." "As digital pathology hardware and software continue to evolve rapidly, selecting a vendor is about more than choosing the best solutions available today - it is also about partnering with an organization that can provide ongoing access to innovation and support," said Clay Hillyer, Senior National Sales Director at Leica Biosystems. "As a global leader in digital pathology, Leica Biosystems is committed to delivering both advanced products and a robust innovation pipeline that helps customers deploy and scale digital pathology to its fullest potential. We are proud to continue that commitment to Versant Diagnostics and PRW Laboratories through this deployment of the Aperio GT Elite solution." The Aperio GT Elite solution is one of the most recent innovations within Leica Biosystems' comprehensive digital and computational pathology ecosystem and expands the company's portfolio of end-to-end solutions-the only provider in the industry to span the full anatomic pathology workflow. Leica Biosystems is trusted by 100% of the Top 50 Hospitals for Cancer, as well as the National Cancer Institute-Designated Cancer Centers, and holds the largest digital pathology instrument install base worldwide. With planned expansion and broader availability of the Aperio GT Elite solution across additional global markets, Leica Biosystems continues to enable access to high-performance digital pathology solutions worldwide. Add The Scientist as a preferred Google source to see more of its trusted coverage.

CEO India Magazine
Mar 25th, 2026
General Electric CEO H. Lawrence Culp Jr.: the leader behind one of the greatest corporate turnarounds.

General Electric CEO H. Lawrence Culp Jr.: the leader behind one of the greatest corporate turnarounds. hemlataMarch 25, 20264 Mins read Introduction. The transformation of General Electric (GE) over the past few years is often cited as one of the most significant corporate turnarounds in modern business history. At the center of this transformation is General Electric CEO H. Lawrence Culp Jr., a leader who brought clarity, discipline, and a long-term vision to a company struggling with complexity and declining performance. When Larry Culp stepped into the role in 2018, GE was facing mounting debt, operational inefficiencies, and a loss of investor confidence. It was no longer the dominant industrial powerhouse it once was. Many believed the company's best days were behind it. However, through a structured and focused approach, he initiated a transformation that would redefine GE's future. His leadership journey reflects a broader shift in global business - where simplicity, accountability, and operational excellence matter more than aggressive expansion. Similar to the strategic discipline seen in Thomas Schinecker's Roche CEO leadership approach, Culp's methods highlight how strong execution can rebuild even the most complex organizations. Early life and academic foundation. H. Lawrence Culp Jr., often referred to as Larry Culp, was born in 1963 in the United States. From an early age, he demonstrated a strong inclination toward structured thinking and leadership. He pursued his undergraduate education at Washington College, followed by an MBA from Harvard Business School. His academic journey provided him with: * A strong foundation in business strategy * Analytical and financial expertise * Leadership and management capabilities These early experiences shaped his disciplined and data-driven leadership style. Career breakthrough at Danaher: building a reputation. Before joining GE, Larry Culp built his reputation at Danaher Corporation, where he served as CEO from 2000 to 2014. During his leadership: * Danaher's revenue and market value grew significantly * The company became a model for operational excellence * He implemented the Danaher Business System (DBS) Understanding the Danaher Business System. DBS is a structured management philosophy that focuses on: * Continuous improvement * Lean operations * Performance measurement * Problem-solving through data This system transformed Danaher into a highly efficient organization and became a benchmark in the corporate world. More importantly, DBS became the foundation of Culp's leadership philosophy - a philosophy he later brought to GE. A historic appointment at General Electric. In 2018, Larry Culp became CEO of General Electric, marking a historic moment as he was the first external leader in the company's long history. At the time, GE was facing serious challenges: * Over $100 billion in debt * Declining stock value * A highly complex organizational structure * Weak operational performance His appointment signaled a major shift - from traditional leadership to a more disciplined and execution-focused approach. Diagnosing the Problem: understanding GE's challenges. Before implementing changes, Culp focused on understanding the root causes of GE's struggles. Key issues identified: * Over-diversification across too many industries * Lack of operational discipline * Poor capital allocation decisions * Complex and inefficient structures Instead of making quick changes, he took a systematic approach - analyzing data, identifying inefficiencies, and prioritizing actions. The turnaround strategy: A step-by-step transformation. The leadership of General Electric CEO H. Lawrence Culp Jr. is best understood through his multi-layered turnaround strategy. 1. Simplification of the organization. GE had become overly complex, with multiple business units and layers of management. Culp focused on: * Removing unnecessary complexity * Flattening organizational structures * Improving communication and accountability This simplification allowed faster decision-making and better execution. 2. Financial discipline and debt reduction. One of his top priorities was fixing GE's financial health. Key actions: * Selling non-core assets * Reducing debt * Improving cash flow * Strengthening the balance sheet This disciplined approach helped restore investor confidence. 3. Strategic focus on core businesses. Instead of trying to be everywhere, GE narrowed its focus to key sectors: * Aviation * Healthcare * Energy This strategic clarity improved operational efficiency and long-term growth potential. 4. Breaking up GE: A bold decision. One of the most significant decisions under his leadership was restructuring GE into separate companies. This move aimed to: * Unlock shareholder value * Allow each business unit to operate independently * Improve focus and agility This strategy reflects modern leadership thinking, similar to Ted Decker's Home Depot leadership, where simplification and focus drive success. 5. Implementation of lean management and operational excellence. Culp introduced lean management practices inspired by DBS. Impact: * Increased productivity * Reduced waste * Improved operational efficiency Employees were encouraged to focus on continuous improvement and measurable outcomes. Leadership style: discipline meets clarity. Larry Culp's leadership style stands out for its simplicity and effectiveness. Key characteristics: 1. Data-Driven decision making. Every decision is backed by data and analysis. 2. Transparency. He maintains clear communication with stakeholders. 3. Accountability. Leaders are responsible for results, not just plans. 4. Long-Term focus. He prioritizes sustainable growth over short-term gains. This approach aligns with leadership philosophies seen in Caterpillar CEO Jim Umpleby's strategy, where operational discipline and long-term thinking are central. Challenges during the turnaround. Transforming a company like GE comes with significant challenges. 1. Legacy systems and culture. Changing long-established systems and mindsets required time. 2. Investor expectations. Stakeholders expected quick results, increasing pressure. 3. Global economic factors. External factors such as economic downturns affected performance. 4. Industry competition. GE operates in highly competitive industries. Despite these challenges, consistent progress has been achieved. Impact and results of the transformation. Under Culp's leadership, GE has shown measurable improvements: * Significant reduction in debt * Improved cash flow and financial stability * Stronger performance in core sectors * Renewed investor confidence The transformation is ongoing, but the results demonstrate the effectiveness of his strategy. Business lessons from Larry Culp's leadership. The journey of GE's transformation offers valuable lessons: 1. Simplify to succeed. Complexity can hinder growth - simplicity enables it. 2. Focus on core strengths. Concentrating on key areas leads to better results. 3. Discipline is non-negotiable. Strong financial and operational discipline is essential. 4. Take bold decisions. Breaking up GE required courage and vision. 5. Think long-term. Sustainable success takes time. Sustainability and innovation at GE. GE is increasingly focusing on sustainability and innovation. Key areas: * Renewable energy solutions * Advanced aviation technology * Healthcare innovation These initiatives position GE as a forward-looking company. For deeper insights into global business transformation and leadership strategies, explore: Future outlook: what lies ahead for GE. The future strategy focuses on: * Independent and focused business units * Continuous innovation * Operational excellence * Sustainable growth GE is evolving into a more agile and efficient organization. Conclusion. The journey of General Electric CEO H. Lawrence Culp Jr. is a masterclass in leadership and transformation. By focusing on simplicity, discipline, and execution, he has led one of the most remarkable corporate turnarounds in recent history. His leadership proves that even the most complex organizations can be rebuilt with the right strategy and mindset. For business leaders, entrepreneurs, and professionals, his journey offers a powerful blueprint for long-term success.

Yahoo Finance
Mar 24th, 2026
Danaher reports Q4 revenue of $6.84B as bioprocessing drives strong finish to the year

Danaher reported Q4 revenues of $6.84 billion, up 4.6% year on year, meeting analysts' expectations. The life sciences company delivered strong performance across its portfolio, particularly in bioprocessing, with improved momentum in diagnostics and life sciences divisions. The research tools and consumables sector overall posted satisfactory Q4 results, with the 10 tracked stocks beating consensus revenue estimates by 1.2%. However, share prices have struggled, declining 18.9% on average since latest earnings. The sector faces challenges including high R&D costs and sensitivity to research funding cycles, but benefits from recurring revenue streams and opportunities in emerging fields like synthetic biology and AI-driven laboratory automation. CEO Rainer Blair highlighted disciplined execution that exceeded margin, earnings and cash flow expectations.

Yahoo Finance
Mar 20th, 2026
Danaher stock drops 30% from highs, presenting entry point into healthcare compounder

Danaher Corporation has drawn investor attention following a pullback of over 30% from its 52-week highs, creating what analysts view as an attractive entry point. The healthcare and life sciences company, known for its Danaher Business System, generates approximately $24 billion in revenue with operating margins near 18%. Whilst near-term headwinds have emerged from a slowdown in biotech funding amongst smaller labs, this pressure is considered cyclical rather than structural. Danaher maintains strong profitability with a healthy balance sheet, including a debt-to-equity ratio of around 0.35. The company remains positioned in long-term secular growth trends including biologics manufacturing, diagnostics and life sciences research. Analysts suggest the recent decline offers an opportunity to acquire shares of a proven compounder at a relative discount, with favourable risk-reward prospects as biotech funding cycles normalise.